Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 23 Dec 2021
Reviewer's report:
Peripheral blood biomarkers associated with clinical outcome in locally advanced gastric cancer
patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A
prospective study. Ding et al. BMC Gastro
The authors present interesting data on an important question in a prospective study. However,
there are some relevant limitations. Almost a third of patients were shown to be non-responders,
what occurs to me as quite high in comparison to other studies.
Abstract:
Please, specifiy peripheral blood biomarkers as this brings already relevant information into the
abstract.
Introduction:
Treatment for locally advanced gastric cancer also may include radiotherapy and surgery.
Patients and Methods:
Recist criteria are not very well established in response assessment in neoadjuvant treatment in
gastric cancer. According to the text, all patients were resected irrespecitve of grade of response.
Grade of histologic regression has shown to be associated with OS. Thus, I recommend to
evaluate SII-PNI score according to grade of histologic regression.
Results:
Definition of PD-L1 overexpression is missing.
Discussion:
Cited article #4 did not investigate checkpoint inhibiton. Please, correct this and cite for example
first published data on checkpoint inhibiton in neoadjuvant setting (The KEYNOTE-811 trial of
dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L,
Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia
P, Chung HC. Nature. 2021 Dec;600(7890):727-730.)
Language: Please, correct language eg with help of a native speaker.
As I am not a statistician, please check the data by a statistician.
Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 23 Dec 2021
Reviewer's report:
Peripheral blood biomarkers associated with clinical outcome in locally advanced gastric cancer
patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A
prospective study. Ding et al. BMC Gastro
The authors present interesting data on an important question in a prospective study. However,
there are some relevant limitations. Almost a third of patients were shown to be non-responders,
what occurs to me as quite high in comparison to other studies.
Abstract:
Please, specifiy peripheral blood biomarkers as this brings already relevant information into the
abstract.
Introduction:
Treatment for locally advanced gastric cancer also may include radiotherapy and surgery.
Patients and Methods:
Recist criteria are not very well established in response assessment in neoadjuvant treatment in
gastric cancer. According to the text, all patients were resected irrespecitve of grade of response.
Grade of histologic regression has shown to be associated with OS. Thus, I recommend to
evaluate SII-PNI score according to grade of histologic regression.
Results:
Definition of PD-L1 overexpression is missing.
Discussion:
Cited article #4 did not investigate checkpoint inhibiton. Please, correct this and cite for example
first published data on checkpoint inhibiton in neoadjuvant setting (The KEYNOTE-811 trial of
dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L,
Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia
P, Chung HC. Nature. 2021 Dec;600(7890):727-730.)
Language: Please, correct language eg with help of a native speaker.
As I am not a statistician, please check the data by a statistician.
Please review this paper.
user
Title: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index
(PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients
receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective
study
Version: 3 Date: 23 Dec 2021
Reviewer's report:
Peripheral blood biomarkers associated with clinical outcome in locally advanced gastric cancer
patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A
prospective study. Ding et al. BMC Gastro
The authors present interesting data on an important question in a prospective study. However,
there are some relevant limitations. Almost a third of patients were shown to be non-responders,
what occurs to me as quite high in comparison to other studies.
Abstract:
Please, specifiy peripheral blood biomarkers as this brings already relevant information into the
abstract.
Introduction:
Treatment for locally advanced gastric cancer also may include radiotherapy and surgery.
Patients and Methods:
Recist criteria are not very well established in response assessment in neoadjuvant treatment in
gastric cancer. According to the text, all patients were resected irrespecitve of grade of response.
Grade of histologic regression has shown to be associated with OS. Thus, I recommend to
evaluate SII-PNI score according to grade of histologic regression.
Results:
Definition of PD-L1 overexpression is missing.
Discussion:
Cited article #4 did not investigate checkpoint inhibiton. Please, correct this and cite for example
first published data on checkpoint inhibiton in neoadjuvant setting (The KEYNOTE-811 trial of
dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L,
Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia
P, Chung HC. Nature. 2021 Dec;600(7890):727-730.)
Language: Please, correct language eg with help of a native speaker.
As I am not a statistician, please check the data by a statistician.
assistant